More than 30% of people in the United States (US) are classified as obese, and over 50% are considered significantly overweight. Importantly, obesity is a risk factor not only for the development of metabolic syndrome but also for many cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is the third leading cause of cancer-related death, and 5-year survival of PDAC remains around 9% in the U.S. Obesity is a known risk factor for PDAC. Metabolic control and bariatric surgery, which is an effective treatment for severe obesity and allows massive weight loss, have been shown to reduce the risk of PDAC. It is therefore clear that elucidating the connection between obesity and PDAC is important for the identification of a novel marker and/or intervention point for obesity-related PDAC risk. In this review, we discussed recent progress in obesity-related PDAC in epidemiology, mechanisms, and potential cancer prevention effects of interventions, including bariatric surgery with preclinical and clinical studies.
Past clinical trials of adjuvant therapy combined with interferon (IFN) alpha, fluorouracil, cisplatin, and radiation improved the 5‐year survival rate of pancreatic ductal adenocarcinoma (PDAC). However, these trials also revealed the disadvantages of the systemic toxicity of IFN and insufficient delivery of IFN. To improve efficacy and tolerability, we have developed an oncolytic adenovirus‐expressing IFN (IFN‐OAd). Here, we evaluated IFN‐OAd in combination with chemotherapy (gemcitabine + nab‐paclitaxel) + radiation. Combination index (CI) analysis showed that IFN‐OAd + chemotherapy + radiation was synergistic (CI <1). Notably, IFN‐OAd + chemotherapy + radiation remarkably suppressed tumor growth and induced a higher number of tumor‐infiltrating lymphocytes without severe side toxic effects in an immunocompetent and adenovirus replication‐permissive hamster PDAC model. This is the first study to report that gemcitabine + nab‐paclitaxel, the current first‐line chemotherapy for PDAC, did not hamper virus replication in a replication‐permissive immunocompetent model. IFN‐OAd has the potential to overcome the barriers to clinical application of IFN‐based therapy through its tumor‐specific expression of IFN, induction of antitumor immunity, and sensitization with chemoradiation. Combining IFN‐OAd with gemcitabine + nab‐paclitaxel + radiation might be an effective and clinically beneficial treatment for PDAC patients.
Herein we report the case of a patient with multiple glucagonomas that have been precisely described with endoscopic ultrasound. A 36‐year‐old woman was referred to our hospital for computed tomography investigation of multiple pancreatic masses. Physical examination was unremarkable; on contrast‐enhanced computed tomography, mass lesions were evident in the head, body, and tail of the pancreas. The mass in the pancreatic head was poorly demarcated and exhibited a faint contrast effect, the one in the pancreatic body was a cystic lesion, and the one in the pancreatic tail was hypervascular. Blood investigations showed that serum glucagon was abnormally high at 7670 pg/ml; glucose tolerance was not impaired. There was no family history that suggested multiple endocrine neoplasia type 1 or von Hippel‐Lindau disease. Endoscopic ultrasound revealed that there were additional masses, which were scattered isoechoic to hyperechoic lesions a few millimeters in size. Ultrasound‐guided fine needle biopsy of the lesion in the pancreatic tail resulted in a diagnosis of a neuroendocrine tumor. Based on these pathologic findings, we performed a total pancreatectomy. A large number of nodules with tumor cells were evident in all cut surfaces of the surgical specimen. Immunostaining was positive for chromogranin A and glucagon, and glucagonoma was therefore diagnosed. It is conceivable that attenuated glucagon action could have contributed to the development of the multiple glucagonomas.
There are no reliable screening tests for pancreatic ductal adenocarcinoma (PDAC). We performed this study to address this issue. Using 206 serum samples from 95 healthy subjects and 111 patients with PDAC, we developed the novel ACAm‐S index, which consists of age, CA19‐9, and methylated somatostatin . The ACAm‐S index showed a sensitivity of 91.0% (101/111) for all stages of PDAC and a specificity of 94.7% (90/95). Notably, its sensitivity was high at 85.4% (35/41), even for Stage I PDAC. The ACAm‐S index may have potential as a blood‐based screening tool for early‐stage PDAC in the general population.